These drugs include agents targeting the prostacyclin, endothelin-1, and nitric oxide pathways [49]; different studies showed a certain degree of clinical status improvement in CTEPH patients [50,51,52]. This evidence concerns the gene EDN1 and chronic thromboembolic pulmonary hypertension.